Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

BGM0504

Stage Phase 3Stale

Sponsor BrightGene Bio-Medical Technology Co

Route oral and injection

Class GLP-1/GIP

Mechanism dual GLP-1 and GIP receptor agonist

Sources

registry, as of 2026-10-15Stale

https://clinicaltrials.gov/study/NCT06704581

A Study of BGM0504 Injection in Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.. Enrollment 652. Conditions Overweight or Obesity. This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an

ClinicalTrials.gov NCT06704581 protocol and results modules

registry, as of 2026-10-15Stale

https://clinicaltrials.gov/study/NCT07658560

A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 200. Conditions Overweight or Obese Participants Without Diabetes. To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.

ClinicalTrials.gov NCT07658560 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT06973681

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 120. Conditions Overweight or Obesity. To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

ClinicalTrials.gov NCT06973681 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT06911203

A Study of BGM0504 in Participants With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 96. Conditions Obesity. To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

ClinicalTrials.gov NCT06911203 protocol and results modules

registry, as of 2026-09-23Stale

https://clinicaltrials.gov/study/NCT07836140

A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Second Affiliated Hospital of Soochow University. Enrollment 60. Conditions Obesity / Overweight. An Investigator-Initiated, Randomized, Open-Label, Active-Controlled Study Comparing the Effects of BGM0504 Injection versus Semaglutide Injection on Insulin Sensitivity and Body Weight in Obese Subjects

ClinicalTrials.gov NCT07836140 protocol and results modules

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT07382908

Bioequivalence Study of BGM0504 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 144. Conditions Overweight/Obesity. This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).

ClinicalTrials.gov NCT07382908 protocol and results modules

registry, as of 2026-10-19Stale

https://clinicaltrials.gov/study/NCT07166081

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 80. Conditions Non-diabetic Overweight or Obese. This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweigh

ClinicalTrials.gov NCT07166081 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07239973

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 75. Conditions Healthy; Non-diabetic Overweight or Obese. A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.

ClinicalTrials.gov NCT07239973 protocol and results modules

publication, as of 2026-11-03

https://pubmed.ncbi.nlm.nih.gov/42755112/

Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. To evaluate the safety, tolerability, ph

PMID 42755112

Studies

A Study of BGM0504 Injection in Participants With Obesity or Overweight

Registry NCT06704581

Phase Phase 3

Status Completed

Enrollment 652

Start 2024-10-29

Primary completion 2026-03-17

Study completion 2026-03-17

Catalyst Primary completion. 2026-03-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

5 mg BGM0504 injection

Dose 5 mg

Regimen once weekly

Weeks 10

Comparator placebo

Population Overweight or Obesity

10 mg BGM0504 injection

Dose 10 mg

Regimen once weekly

Weeks 10

Comparator placebo

Population Overweight or Obesity

15 mg BGM0504 injection

Dose 15 mg

Regimen once weekly

Weeks 10

Comparator placebo

Population Overweight or Obesity

BGM0504 placebo

Regimen once weekly

Weeks 10

Population Overweight or Obesity

A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

Registry NCT07658560

Phase Phase 2

Status Recruiting

Enrollment 200

Start 2026-06-29

Primary completion 2027-02-28

Study completion 2027-02-28

Catalyst Primary completion. 2027-02-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

The dose1 group

Regimen once daily

Weeks 20

Comparator placebo

Population Overweight or Obese Participants Without Diabetes

The dose2 group

Regimen once daily

Weeks 20

Comparator placebo

Population Overweight or Obese Participants Without Diabetes

The dose3 group

Regimen once daily

Weeks 20

Comparator placebo

Population Overweight or Obese Participants Without Diabetes

The dose4 group

Regimen once daily

Weeks 20

Comparator placebo

Population Overweight or Obese Participants Without Diabetes

Placebo group

Regimen once daily

Weeks 20

Population Overweight or Obese Participants Without Diabetes

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

Registry NCT06973681

Phase Phase 2

Status Completed

Enrollment 120

Start 2023-10-13

Primary completion 2024-09-13

Study completion 2024-09-13

5 mg BGM0504

Dose 5 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight or Obesity

10 mg BGM0504

Dose 10 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight or Obesity

15 mg BGM0504

Dose 15 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Overweight or Obesity

Placebo

Regimen once weekly

Weeks 24

Population Overweight or Obesity

A Study of BGM0504 in Participants With Obesity

Registry NCT06911203

Phase Phase 2

Status Completed

Enrollment 96

Start 2025-04-09

Primary completion 2026-01-14

Study completion 2026-01-14

Catalyst Primary completion. 2026-01-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BGM0504

Population Obesity

Tirzepatide

Population Obesity

A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

Registry NCT07836140

Phase Phase 2

Status Completed

Enrollment 60

Start 2024-04-22

Primary completion 2025-04-25

Study completion 2026-04-30

Catalyst Primary completion. 2025-04-25. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide

Population Obesity / Overweight

BGM0504

Population Obesity / Overweight

Bioequivalence Study of BGM0504 Injection

Registry NCT07382908

Phase Phase 1

Status Completed

Enrollment 144

Start 2025-12-29

Primary completion 2026-04-09

Study completion 2026-04-09

Catalyst Primary completion. 2026-04-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BGM0504 Injection multi-dose pen

Population Overweight/Obesity

BGM0504 Injection single-dose pen

Population Overweight/Obesity

BGM0504 Injection single-dose pen-2

Population Overweight/Obesity

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Registry NCT07166081

Phase Phase 1

Status Completed

Enrollment 80

Start 2025-08-11

Primary completion 2026-03-16

Study completion 2026-07-15

Catalyst Primary completion. 2026-03-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Regimen daily

Comparator placebo

Population Non-diabetic Overweight or Obese

Cohort 2

Regimen daily

Comparator placebo

Population Non-diabetic Overweight or Obese

Cohort 3

Regimen daily

Comparator placebo

Population Non-diabetic Overweight or Obese

Placebo

Regimen daily

Population Non-diabetic Overweight or Obese

Cohort 4

Regimen daily

Comparator placebo

Population Non-diabetic Overweight or Obese

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

Registry NCT07239973

Phase Phase 1

Status Completed

Enrollment 75

Start 2025-10-24

Primary completion 2026-03-05

Study completion 2026-03-05

Catalyst Primary completion. 2026-03-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BGM0504 tablets

Regimen once daily

Comparator placebo

Population Healthy; Non-diabetic Overweight or Obese

Placebo tablets

Regimen once daily

Population Healthy; Non-diabetic Overweight or Obese